Wells Fargo & Company MN trimmed its stake in Avantor, Inc. (NYSE:AVTR – Free Report) by 2.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 720,724 shares of the company’s stock after selling 19,450 shares during the quarter. Wells Fargo & Company MN owned approximately 0.11% of Avantor worth $16,454,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Fifth Third Bancorp raised its position in Avantor by 125.3% during the fourth quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after buying an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Avantor by 565.5% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock worth $30,000 after purchasing an additional 1,131 shares during the last quarter. Gladius Capital Management LP bought a new stake in shares of Avantor during the 4th quarter worth $42,000. Montag A & Associates Inc. acquired a new position in Avantor during the 4th quarter worth $43,000. Finally, GAMMA Investing LLC bought a new position in Avantor during the fourth quarter worth $47,000. 95.08% of the stock is owned by institutional investors and hedge funds.
Avantor Price Performance
Avantor stock opened at $24.09 on Friday. Avantor, Inc. has a 52 week low of $16.63 and a 52 week high of $26.16. The firm has a market cap of $16.36 billion, a P/E ratio of 61.77, a P/E/G ratio of 2.39 and a beta of 1.36. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.61. The business’s fifty day moving average is $24.80 and its two-hundred day moving average is $23.49.
Avantor (NYSE:AVTR – Get Free Report) last released its earnings results on Friday, April 26th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. The firm had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.68 billion. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The business’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 EPS. Equities research analysts forecast that Avantor, Inc. will post 1.01 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
AVTR has been the topic of several recent research reports. UBS Group lifted their price objective on Avantor from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Citigroup increased their price objective on shares of Avantor from $24.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Barclays lifted their target price on shares of Avantor from $27.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Thursday, April 18th. Finally, Evercore ISI lifted their price objective on Avantor from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.71.
Check Out Our Latest Report on Avantor
Avantor Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Recommended Stories
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Avantor and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
